Alphatec/$ATEC
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Alphatec
Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others. Its procedural offerings are designed to address the underlying causes of spinal pathology by advancing the three fundamental objectives of spine surgery: (1) decompression of neural elements, (2) stabilization of spinal segments, and (3) restoration and maintenance of proper spinal alignment.
- Ticker
- $ATEC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 913
- Headquarters
- Carlsbad, United States
- Website
- www.atecspine.com
Alphatec Metrics
BasicAdvanced
$1.1B
-
-$0.56
0.78
-
Price and volume
Market cap
$1.1B
Beta
0.78
52-week high
$23.29
52-week low
$6.81
Average daily volume
3.3M
Financial strength
Current ratio
2.363
Quick ratio
1.055
Long term debt to equity
27.918
Total debt to equity
28.324
Interest coverage (TTM)
-0.55%
Profitability
EBITDA (TTM)
52.925
Gross margin (TTM)
71.25%
Net profit margin (TTM)
-10.35%
Operating margin (TTM)
-3.05%
Effective tax rate (TTM)
2.04%
Revenue per employee (TTM)
$920,000
Management effectiveness
Return on assets (TTM)
-2.02%
Return on equity (TTM)
-308.06%
Valuation
Price to revenue (TTM)
1.3
Price to book
-469.18
Price to tangible book (TTM)
-6.25
Price to free cash flow (TTM)
-104.575
Free cash flow yield (TTM)
-0.96%
Free cash flow per share (TTM)
-0.067
Growth
Revenue change (TTM)
15.34%
Earnings per share change (TTM)
-46.42%
3-year revenue growth (CAGR)
23.09%
10-year revenue growth (CAGR)
20.70%
3-year earnings per share growth (CAGR)
-28.12%
10-year earnings per share growth (CAGR)
-18.23%
What the Analysts think about Alphatec
Analyst ratings (Buy, Hold, Sell) for Alphatec stock.
Analyst projections of the future price of Alphatec stock.
Bulls say / Bears say
ATEC’s core surgical platform is still gaining users: Q3 case volumes rose 20% and new surgeon adoption rose 25%, while surgical hardware revenue grew 17%. That supports further growth if new surgeons keep expanding their use of the company’s products. (Alphatec)
Profitability is improving alongside sales: Q3 adjusted EBITDA rose to $38m, its margin expanded by four percentage points year on year, and the company generated $6m of free cash flow. It expects full-year adjusted EBITDA of about $137m, up sharply on 2025. (Alphatec)
EOS Insight could help turn imaging customers into surgical customers: ATEC reported that implant revenue at established Insight accounts rose about 32% within six months of implementation. If that cross-selling continues, it could add value beyond EOS equipment sales. (The Motley Fool)
Biologics attachment is weakening revenue per case: management said it fell 5% in Q3, and cut its full-year revenue outlook to about $862m from $882m in August. The revised outlook assumes flat biologics revenue for the year, leaving little near-term recovery in this growth contributor. (Alphatec, Alphatec)
Data summarised monthly by Lightyear AI. Last updated on 30 Oct 2026.
Alphatec Financial Performance
Revenues and expenses
Alphatec Earnings Performance
Company profitability
Upcoming events
No upcoming events
Alphatec News
AllArticlesVideos
Funds containing Alphatec
Fund name | Fund size | $ATEC weighting |
|---|---|---|
iShares Ageing Population$AGED | $953M | 0.14% |
iShares Ageing Population£AGES | $953M | 0.14% |
iShares Ageing Population€AGED | $903M | 0.14% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.05% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.05% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.